Virpax Pharmaceuticals Q2 2024 GAAP EPS $(1.75) May Not Be Comparable To $(0.61) Estimate
Portfolio Pulse from Benzinga Newsdesk
Virpax Pharmaceuticals reported a Q2 2024 GAAP EPS of $(1.75), which is significantly lower than the $(0.61) estimate. This discrepancy may impact investor sentiment negatively.
August 13, 2024 | 11:32 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Virpax Pharmaceuticals reported a Q2 2024 GAAP EPS of $(1.75), which is significantly lower than the $(0.61) estimate. This discrepancy may impact investor sentiment negatively.
The significant miss in EPS compared to the estimate is likely to negatively impact investor sentiment and could lead to a short-term decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100